The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, and US-based MIT – Koch Institute for Integrative Cancer Research have announced a strategic collaboration to advance AI-enabled oncology research, translational science and bioconvergence innovation.
Leveraging Abu Dhabi's intelligent life science ecosystem, the partnership will connect world-class research expertise with the infrastructure, talent and capabilities required to accelerate the translation of scientific discovery into real-world impact.
Aligned with UAE's National Cancer Strategy and MIT's research excellence, the partnership aims to advance breakthrough cancer research with an emphasis on addressing climate-health and population-specific oncology challenges.
This will be achieved through the development and implementation of large-scale, multi-institutional clinical trials and translational research studies, participation in MIT's Bioconvergence Cancer Alliance and establishment of shared research databases and biobanks enabling population-specific cancer research.
Beyond research, the collaboration will focus on building the next generation of talent and innovation at the intersection of AI and oncology. Through physician-scientist fellowships, bilateral exchange programmes and joint learning opportunities, DoH and MIT will equip healthcare professionals with advanced capabilities in clinical oncology, artificial intelligence and computational biology.
The partnership will also establish a bioconvergence incubator to support the growth of high-potential startups, connecting innovators with mentorship, expertise and investment to accelerate the translation of scientific discoveries into real-world health solutions.
